The Contains:Courage® FARE Summit 2019 was held Nov. 1-3 at the Gaylord National Resort & Convention Center near Washington, D.C. This dynamic summit meeting drew over 1,000 participants. Tweens, teens and adults living with food allergy came together with family members, health professionals and other allies in the nation’s largest ever educational food allergy event for families.
Edited by Toni Taylor and Jon Terry Allergy Advocacy Association Co-Founders November 20th, 2019
Dealing with life threatening allergies by patiently, courageously putting one foot in front of the other for the long haul, eventually achieves the desired result. This year’s Food Allergy Research and Education teen conference was a great reminder of this. There were some exciting updates in the areas of product development, advocacy, and research.
This event was a timely reminder that those dealing with anaphylaxis cannot be reduced to their allergies. In addition to courageous, they are accomplished self-advocates, creative, curious, and entrepreneurial.
Regarding health care costs, it is no surprise to any American that they continue to increase for everyone year after year. And for individuals and families afflicted with peanut allergies, insurance claims are skyrocketing even higher. Are there any new alternatives and options for prevention and treatment of anaphylaxis? The Economist Daily chart: "The Prevalence of Peanut Allergy Has Trebled in 15 Years" summarizes the trend.
Medical claims are twice as high for people who have received treatment for a peanut allergy as for those who have not, and for people with a diagnosis of peanut allergy, those claims are 10 times as high, findings from a new study show.
Most of us are certainly aware that the number of people with severe food allergies is increasing rapidly. But there is hope for the future, as an advisory panel at the Food and Drug Administration (FDA) recently voted to approve a new treatment for peanut allergies in children. Called Palforzia, the drug seeks to treat peanut-allergy sufferers by exposing them to increasing amounts of pharmaceutical-grade peanut protein.
FOOD ALLERGIES have plagued humans for thousands of years. In the fifth century BC Hippocrates noted that although some people could eat their fill of cheese “without the slightest hurt…others come off badly.” The difference, he observed, “lies in the constitution of the body.”
One and all had a fantastic time at the second annual Allergy Action Awards gala. With tables decorated with teal pumpkins, along with raffle baskets and goodie bags, we celebrated those who have gone above and beyond the call of duty to help keep our community safe. Read all about our award recipients and how proceeds from the event will help to continue our work on educating the community about what to do if someone is experiencing anaphylaxis. Looking forward to seeing you there next year!
Action Awards Gala is BOFFO!!!***
By Suzanne Driscoll October 27, 2019
The Allergy Advocacy Association Awards Gala was held at ARTISAN Works in Rochester NY on October 10th. Our audience enjoyed fabulous entertainment, food and fun!
Proceeds from ticket sales will be used for training personnel at day care centers, summer camps, college campuses and other public venues on how to recognize someone having a severe allergic reaction and how to administer epinephrine.
There is justice at last, with Mylan, the maker of EpiPens, being fined $30 million for over charging Medicaid by classifying it as a “generic” drug, rather than a branded one. Also, investors were kept in the dark about Mylan’s EpiPen misclassification and the potential loss Mylan faced as a result of the pending investigation.
The Securities and Exchange Commission today announced charges against Pennsylvania-based pharmaceutical company Mylan N.V. for accounting and disclosure failures relating to a Department of Justice (DOJ) probe into whether Mylan overcharged Medicaid by hundreds of millions of dollars for EpiPen, its largest revenue and profit generating product. Mylan agreed to pay $30 million to settle the SEC’s charges.